Thomas Steyer’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-2,164,663
| Closed | -$373M | – | 340 |
|
|
2021
Q3 | $373M | Sell |
2,164,663
-335,337
| -13% | -$43.9M | 1.74% | 16 |
|
|
2021
Q2 | $314M | Sell |
2,500,000
-100,000
| -4% | -$12.6M | 1.28% | 26 |
|
|
2021
Q1 | $353M | Hold |
2,600,000
| – | – | 1.75% | 18 |
|
|
2020
Q4 | $333M | Hold |
2,600,000
| – | – | 2% | 19 |
|
|
2020
Q3 | $293M | Buy |
2,600,000
+500,000
| +24% | +$49.8M | 2.02% | 20 |
|
|
2020
Q2 | $200M | Sell |
2,100,000
-75,000
| -3% | -$7.23M | 1.6% | 22 |
|
|
2020
Q1 | $195M | Buy |
2,175,000
+175,000
| +9% | +$13.6M | 1.68% | 21 |
|
|
2019
Q4 | $106M | Sell |
2,000,000
-400,000
| -17% | -$18.2M | 0.72% | 36 |
|
|
2019
Q3 | $94.8M | Buy |
2,400,000
+25,000
| +1% | +$1.08M | 0.72% | 35 |
|
|
2019
Q2 | $97.6M | Hold |
2,375,000
| – | – | 0.63% | 35 |
|
|
2019
Q1 | $111M | Buy |
2,375,000
+275,000
| +13% | +$12.1M | 0.83% | 34 |
|
|
2018
Q4 | $91.5M | Buy |
2,100,000
+259,268
| +14% | +$13M | 0.67% | 36 |
|
|
2018
Q3 | $105M | Buy |
1,840,732
+439,732
| +31% | +$21.6M | 0.62% | 33 |
|
|
2018
Q2 | $68M | Hold |
1,401,000
| – | – | 0.42% | 44 |
|
|
2018
Q1 | $54.8M | Buy |
1,401,000
+313,000
| +29% | +$13.3M | 0.38% | 46 |
|
|
2017
Q4 | $46.2M | Buy |
1,088,000
+125,000
| +13% | +$4.69M | 0.38% | 43 |
|
|
2017
Q3 | $35.9M | Buy |
+963,000
| New | +$33.4M | 0.32% | 48 |
|
Thomas Steyer's XLRN Position: Q4 2021 in Review
Thomas Steyer sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 2,164,663 shares — an estimated $373M sold.
Thomas Steyer first reported a position in XLRN in Q3 2017 and held it in 17 quarters. The position peaked at $373M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Thomas Steyer reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Thomas Steyer sold 2,164,663 Acceleron Pharma shares in Q4 2021, an estimated $373M.
- Thomas Steyer first reported a position in Acceleron Pharma in Q3 2017 and held it in 17 quarters.
- Thomas Steyer's Acceleron Pharma position peaked at $373M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Farallon Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.